(Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to Commission file number 001-39128 Momentus Inc. (Exact name of registrant as specified in its charter) Delaware 84-1905538 (State or other ...

Financial Performance - Banzai generated revenue of approximately $3.4 million for the three months ended March 31, 2025, compared to $1.1 million for the same period in 2024, representing a year-over-year increase of approximately 209%[257]. - The company incurred net losses of approximately $3.6 million for the three months ended March 31, 2025, compared to $4.3 million for the same period in 2024, indicating a reduction in losses[257]. - For the three months ended March 31, 2025, Banzai reported total revenue of approximately $3,379 thousand, an increase of approximately $2,300 thousand, or 213.2%, compared to the same period in 2024[334]. - Banzai's gross profit for the three months ended March 31, 2025, was approximately $2,773 thousand, an increase of approximately $2,075 thousand, or 297.3%, compared to the prior year[336]. - Banzai reported a net loss of approximately $3,644 thousand for the three months ended March 31, 2025, a decrease of approximately $647 thousand, or 15.1%, compared to the net loss of approximately $4,291 thousand in the prior year[342]. - The overall increase in operating expenses was approximately $3.6 million, which included significant contributions from new acquisitions and increased operational costs[344]. - For the three months ended March 31, 2025, the company's Adjusted EBITDA loss was approximately $1.7 million, reflecting a 15.2% increase in loss compared to a loss of approximately $1.5 million for the same period in 2024[361]. Customer Metrics - Banzai's customer base grew to over 3,070 customers as of March 31, 2025, with a significant increase in multi-host Demio customers from 14 to 163 since January 1, 2021[255]. - For the three months ended March 31, 2025, Demio generated 27.0% of total revenue, compared to 99.0% in the same period of 2024[303]. - Average Monthly Net Revenue Retention (NRR) for Demio was 98.7% for the three months ended March 31, 2025, up from 97.2% in 2024[307]. - New Customer Average Customer Value (ACV) for Demio increased to $5,619 in Q1 2025 from $1,484 in Q1 2024[310]. - Customer Acquisition Cost (CAC) for Demio rose to $2,258 in Q1 2025, compared to $1,220 in Q1 2024[314]. - Average Monthly Revenue Churn for Demio was 5.1% in Q1 2025, slightly down from 5.2% in Q1 2024[317]. - Customer Lifetime Value (LTV) for new customers increased to $9,261 in Q1 2025 from $2,376 in Q1 2024[321]. - The LTV/CAC ratio for Demio improved to 5.9 in Q1 2025, compared to 2.0 in Q1 2024, indicating enhanced efficiency in sales and marketing[325]. Mergers and Acquisitions - The company completed the merger with OpenReel on December 18, 2024, with a merger consideration of $19.6 million, consisting of 930,558 shares of Banzai Common Stock and 11,769,501 Pre-Funded Warrants[261]. - Banzai acquired Vidello Limited for approximately $2.7 million in cash and 898,204 shares of Class A common stock, with Vidello generating over $6.5 million in TTM revenue and $2 million in TTM EBITDA[262][263]. - The company entered into a merger agreement with Act-On Software Inc., with an aggregate merger consideration of approximately $35.05 million, payable in cash and shares of Class A Common Stock[265]. - The Business Combination required the Company to incur additional annual expenses related to public company regulatory requirements[331]. Financial Position and Capital Structure - Banzai's accumulated deficit reached $81.9 million as of March 31, 2025, up from $78.3 million as of December 31, 2024[257]. - As of March 31, 2025, the company reported a working capital deficit of approximately $26.6 million and an accumulated deficit totaling approximately $81.9 million[364]. - The company has significant negative industry and economic trends that could lead to future impairments of goodwill, impacting its financial condition[356]. - As of March 31, 2025, the company had cash of approximately $0.8 million, indicating liquidity challenges[363]. - The total capital expenditure commitments and financing requirements as of March 31, 2025, amounted to approximately $14.1 million, with $6.1 million due within one year[373]. Debt and Financing Activities - The Company raised approximately $4.4 million from a private placement, with net proceeds intended for general corporate purposes and working capital[284]. - The Company issued 1,597,944 shares to creditors in exchange for the cancellation of $5,068,547 of debt as part of a debt reorganization plan[289]. - The Company entered into a convertible promissory note with a principal amount of $3,500,000, with a conversion price of $2.00 per share[296]. - The Company completed a public offering of 104,556 shares at a price of $9.00 per share, along with warrants exercisable into 450,000 shares[278]. - The Company raised approximately $7.1 million through the issuance of shares and approximately $3.1 million through additional convertible notes during the three months ended March 31, 2025[364]. - The Company has not yet secured financing for the AO Merger, creating uncertainty about its completion[273]. - The Company issued a subordinated secured promissory note for an aggregate principal amount of $4,000,000, receiving proceeds of $2,044,105 after fees and prepayments[300]. - The Company recorded a loss on debt extinguishment of approximately $6.5 million related to the consolidation of the Old CP BF Notes into a single convertible note[374]. - The total debt carrying value as of March 31, 2025, is $15,327,000, which includes various debt instruments such as the Agile Notes and 1800 Diagonal Notes[402]. Stock and Equity Transactions - The Company approved a reverse stock split at a ratio of 1-for-50, effective September 19, 2024[275]. - The Company issued 337,773 RSUs to executives as part of the fiscal 2024 bonus plan[295]. - The Company entered into a securities purchase agreement for a private placement of pre-funded warrants and Series A and B warrants, with a combined purchase price of $4.249 per warrant[280]. - The Company issued 30,000 shares to a creditor in exchange for the cancellation of $16,666 of debt[299]. - The Company has a total of approximately $7.4 million in debt principal related to the 15.5% CP BF Convertible Notes due in the long term[373]. Operational Metrics - The cost of revenue for the same period was approximately $606 thousand, representing an increase of approximately $225 thousand, or 59.1%, primarily due to additional costs from OpenReel and Vidello products[335]. - Total operating expenses for the same period were approximately $7,680 thousand, an increase of approximately $3,579 thousand, or 87.3%, driven by expenses from OpenReel and Vidello, as well as increases in salaries and marketing[337]. - The provision for income tax expense for the three months ended March 31, 2025, was $74 thousand, compared to no provision in the same period in 2024[339]. - The company recognized a gain on extinguishment of debt of approximately $4.3 million during the three months ended March 31, 2025, compared to $0.5 million in the same period in 2024[343]. Cash Flow - Net cash used in operating activities was approximately $5.0 million for the three months ended March 31, 2025, compared to $2.1 million for the same period in 2024, representing a 135.0% increase in cash outflow[368]. - The company reported a net cash provided by financing activities of approximately $7.3 million for the three months ended March 31, 2025, a significant increase of 599.6% compared to $1.1 million in 2024[367]. - Net cash provided by financing activities for the three months ended March 31, 2025, was approximately $7.3 million, primarily from proceeds of convertible debt financing of approximately $3.2 million and issuance of shares under the SEPA agreement of approximately $6.7 million[370].

Banzai International, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39826 (Exact name of Registrant as specified in its Charter) Delaware 85-3118980 (State or ...

For the quarterly period ended March 31, 2025 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to__________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Nevada 45-2808620 300 Aragon Avenue, Suite 375 Coral Gables ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to ____________. Commission File Number 001-40023 GT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. COMMISSION FILE NUMBER: 001-41463 (Exact name of registrant as specified in its charter) Delaware 46-5211056 (State or other jurisdiction of in ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to__________ Commission File Number: 001-40768 OMNIQ Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of incorpo ...

Financial Performance - The company generated research and development revenue of $6,707,000 for the three months ended March 31, 2025, representing a 6.0% increase from $6,326,000 in the same period of 2024[115]. - Gross profit for the same period was $3,168,000, with a gross margin of 47.2%, compared to a gross profit of $2,945,000 and a gross margin of 46.6% in 2024[101]. - The company reported a net income of $2,897,000 for the three months ended March 31, 2025, a significant improvement from a net loss of $3,205,000 in the prior year[114]. - Operating loss for the three months ended March 31, 2025, was $896,000, a reduction from an operating loss of $2,143,000 in the same period of 2024[114]. - Adjusted EBITDA for the three months ended March 31, 2025, was $(694) thousand, improving from $(1,857) thousand in the comparable period in 2024[126]. - General and administrative expenses decreased by 20.1% to $4.1 million for the three months ended March 31, 2025, down from $5.1 million in 2024[119]. - Net cash used in operating activities decreased by approximately $1.2 million to $(1.5) million for the three months ended March 31, 2025[136]. - Net cash provided by financing activities increased to approximately $10.3 million for the three months ended March 31, 2025, compared to $8.0 million in 2024[137]. Contracts and Funding - The company has received a new contract with BARDA, providing up to $150 million in funding, including an initial award of approximately $54.9 million for clinical validation of the DeepView System[95]. - The total potential support from BARDA is nearly $272.9 million, including the new PBS BARDA Contract valued at $54.9 million[128]. - The company has received a $4.9 million grant from MTEC, intended to support military battlefield burn evaluation via a handheld DeepView System device[96]. Clinical Studies and Product Development - The company completed enrollment of a pivotal clinical study with 267 patients, including 42 pediatric patients, across 22 sites in the United States[93]. - The company anticipates two revenue streams from the DeepView System: a software as a medical device (SaMD) model and an imaging device component[97]. - The company has not generated any product revenue to date, relying on contract development and research services for revenue[94]. Shareholder and Financing Activities - The company began trading its shares on the Nasdaq under the symbols "MDAI" and "MDAIW" following the completion of a Business Combination on September 12, 2023[99]. - The company entered into a Loan and Security Agreement allowing it to borrow up to $15.0 million, with an initial drawdown of $8.5 million[129]. - Avenue Financing includes warrant coverage equal to 8.5% of the total funding commitment, with an exercise price of $1.66[140]. - Spectral IP received a $1.0 million investment from an affiliate of its largest stockholder for developing artificial intelligence intellectual property[141]. - The Spectral IP Note was amended to reduce the annual interest rate from 8% to 4% and extend the term through March 18, 2026[142]. - The holder of the Spectral IP Note converted it into 540,996 shares of Common Stock at a 5% discount to the closing price[142]. Cash Position and Risks - As of March 31, 2025, the company had approximately $14.1 million in cash and an accumulated deficit of approximately $45.3 million[127]. - The company maintains a significant amount of cash, with interest rates on current borrowings at Prime plus 5.25%[152]. - The company has not recognized any losses from credit risks on cash, indicating a low exposure to significant credit risk[154]. - Inflationary pressures may adversely affect the company's gross margin and cash flows if costs continue to rise significantly[156]. Company Classification - The company is classified as an emerging growth company, allowing it to delay the adoption of certain accounting standards[147]. - One customer, a U.S. government agency, represents the majority of the company's research and development revenue and accounts receivable[155]. - The company has no off-balance sheet arrangements during the periods presented[143].